Management of subcutaneous insulin resistance

What are the methods for management blood glucose in diabetic patients with subcutaneous insulin resistance?

Searched PubMed and EMBASE; case reports only

For a review article on the condition: Diabetes Metab. 2003 Nov;29(5):539-46

Citation, full-text, patients’ summary

Diabetes Care. 2008 Mar;31(3):e11. 1 patient with type 2 DM Improvement of subcutaneous insulin resistance with nafamostat (protease inhibitor) ointment

Diabetes Metab. 2005 Nov;31(5):496-8. 3 patients with type 1 DM and 1 patient with unexplained non-insulin deficient diabetes 2 patients had been treated unsuccessfully with insulin mixed with aprotinin. Disease control was obtained by IP insulin delivery from an implantable pump

Diabetes Res Clin Pract. 2001 Dec;54(3):209-12. 1 patient with type 1 DM Continuous subcutaneous infusion (CSII) with regular insulin or insulin lispro caused hyperglycemic periods. Tried adding heparin to insulin lispro in CSII. Increase of serum insulin level and improvement of glycemic control. Tried regular insulin plus heparin but not effective.

Diabetes Research. 1986;3(7):387-389. 1 patient with type 1 DM After 18 months’ aprotinin therapy, subcutaneous insulin resistance disappeared.

Diabetes Research. 1984;1(2):83-88. 1 patient with Type 1 DM Insulin resistance was treated successfully by a totally implantable insulin infusion device (‘INFUSAID’). After pump installation, plasma glucose control was maintained and serum lipid and glycosylated haemoglobin (HbA1) levels returned to normal.


About Amy

Clinical Informationist at EUH Branch Library
This entry was posted in Background question, Therapy. Bookmark the permalink.